CervoMed Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
CervoMed Inc. (CRVO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $858.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2025-03-17
- CervoMed Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was $858.00K.
- CervoMed Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-12-31 was -$10.85M.
- CervoMed Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-09-30 was -$4.78M.
- CervoMed Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-06-30 was $212.00K.
- CervoMed Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$5.42M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $858.00K 10-Q · filed 2024-05-14 | -$9.99M derived: sum of 2 quarters · filed 2025-03-17 | -$14.77M derived: sum of 3 quarters · filed 2025-03-17 | -$14.56M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-12-31 | -$10.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$15.63M derived: sum of 2 quarters · filed 2025-03-17 | -$15.41M derived: sum of 3 quarters · filed 2025-03-17 | -$5.42M 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$4.78M 10-Q · filed 2024-11-12 | $4.78M 10-Q · filed 2023-11-13 | -$4.57M derived: sum of 2 quarters · filed 2024-11-12 | $5.42M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $212.00K 10-Q · filed 2024-08-09 | -$646.00K 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | -$858.00K 10-Q · filed 2024-08-09 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | -$2.39M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |